Skip to main content
Figure 3 | Arthritis Research & Therapy

Figure 3

From: A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin®for treatment of osteoarthritis of the knee

Figure 3

Reduction of Synovial MMP-3 levels. Presented are the matrix metalloproteinase (MMP)-3 levels in synovial fluid collected from 5-Loxin® treated and placebo patients with osteoarthritis. At day 90 there was no significant change in MMP-3 concentration in the placebo group compared with baseline. In comparison with the placebo group, at the end of the study the groups receiving100 mg/day and 250 mg/day 5-Loxin® showed 31.37% (P = 0.002) and 46.4% (P < 0.001) reductions in MMP-3 concentration, respectively. Change in MMP-3 concentration between the active treatment groups was not significant (P = 0.213). Each bar represents mean concentration of MMP-3 (ng/ml synovial fluid) ± standard deviation.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us